Tech Company Financing Transactions
Pan Cancer T Funding Round
Pan Cancer T, based in Rotterdam, raised $11.6 million in funding from InnovationQuarter Capital and Thuja Capital.
Transaction Overview
Company Name
Announced On
12/8/2025
Transaction Type
Venture Equity
Amount
$11,600,000
Round
Undisclosed
Investors
InnovationQuarter Capital (Nina Satih)
Proceeds Purpose
The company intends to use the funds to advance its lead program, PCT1:CO-STIM, into a first-in-human clinical trial for women with triple-negative breast cancer (TNBC).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Marconistraat 16
Rotterdam, 3029
The Netherlands
Rotterdam, 3029
The Netherlands
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer. The Company´s products are based on a form of T cell therapy called TCR-T therapy. It exploits the abilities of T cells -- the primary natural immune effector cell -- to recognize and kill tumor cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rachel Abbott
Chief Financial Officer
Lars Ottevanger
Chief Medical Officer
Tom Holdich
VP - Bus. Development
Reinout Hesselink
VP - R & D
Dora Hammerl
Browse more venture capital transactions:
Prev: 12/8/2025: TomNext venture capital transaction
Next: 12/8/2025: Tuhk venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on funding rounds that are announced publicly. VC transactions on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs